MONOCLONAL ANTIBODIES PRODUCTION

MABs can be used directly to induce an inflammatory response to tumor cells, or to

block receptors; they can be conjugated with a cytotoxic or radioactive molecule such as Iodine
131. By attaching liposomes containing cytotoxic drugs to single chain antibody constructs,
anticancer drugs can be delivered effectively to the cell interior. Bi-specific MABs can be used
to accumulate cytotoxic cells or molecules at the target site. The ready access of MABs to cells
in the general circulation has resulted in many of the targets being hematological disease such as
blood cancers. The neutralization of circulating immune cells or clotting components has also
been achieved. Commercial and academic laboratories are developing antibodies to neutralize
particular classes of T cells to control diseases such as psoriasis, and to limit tissue damage
following cardiac arrest or stroke.

STEPS INVOLVED IN PRODUCTION OF MONOCLONAL ANTIBODIES

1. Immunization and Myeloma preparation

2. Fusion
3. Screening
4. Cloning
5. Cell line characterization
 Growth
 Secretion
 Cryostability
6. Antibody characterization
 Isotype
 Affinity
 Specificity
 Storage
7. Expansion in vitro
 Pilot purification
8. Expansion in vivo
 Pilot purification
9. Large scale production
10. Downstream processing
11. Application